Great Point Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Great Point Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400,000	Closed	-$12M	–	42
2022 Q1	$12M	Sell	400,000 -100,000	-20%	-$2.71M	2.89%	16
2021 Q4	$13.3M	Buy	500,000 +302,000	+153%	+$9.11M	2.94%	13
2021 Q3	$7.19M	Buy	198,000 +48,000	+32%	+$1.89M	1.67%	26
2021 Q2	$6.51M	Buy	+150,000	New	+$5.66M	1.37%	27
2018 Q3	–	Sell	-340,784	Closed	-$9.64M	–	37
2018 Q2	$9.64M	Sell	340,784 -517,161	-60%	-$18.4M	1.34%	26
2018 Q1	$30.4M	Buy	857,945 +69,087	+9%	+$2.77M	4.51%	11
2017 Q4	$30.6M	Sell	788,858 -121,711	-13%	-$4.63M	5.22%	7
2017 Q3	$23.1M	Hold	910,569	–	–	4.5%	9
2017 Q2	$24.9M	Hold	910,569	–	–	4.45%	9
2017 Q1	$30.1M	Buy	+910,569	New	+$23.2M	5.99%	5
2016 Q3	–	Sell	-5,000	Closed	-$112K	–	44
2016 Q2	$112K	Sell	5,000 -10,787	-68%	-$268K	0.03%	37
2016 Q1	$328K	Buy	+15,787	New	+$389K	0.12%	31

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Point Partners's RIGL Position: Q2 2022 in Review

Great Point Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 400,000 shares — an estimated $12M sold.

Great Point Partners first reported a position in RIGL in Q1 2016 and held it in 12 quarters. The position peaked at $30.6M in Q4 2017. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

Great Point Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Great Point Partners sold 400,000 Rigel Pharmaceuticals shares in Q2 2022, an estimated $12M.
Great Point Partners first reported a position in Rigel Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Great Point Partners's Rigel Pharmaceuticals position peaked at $30.6M in Q4 2017.
135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Great Point Partners's 13F filing for Q2 2022, filed 15 Aug 2022.